NCE-1 Intelligence & Market Opportunity

Wainua

Eplontersen

Neuroprotective

Subcutaneous Injection

Wainua is a subcutaneous injection designed for adults managing nerve damage caused by hereditary transthyretin-mediated amyloidosis (ATTRv‑PN). It works via an antisense therapy that reduces the abnormal protein buildup damaging the nerves.

Approval Date

21-Dec-23

NCE-1 Date

21-Dec-27

NCE Date

21-Dec-28

Commercial snapshot

Market performance & projections

Revenue ($M)

261

CAGR (%)

0.6484

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

418

2027

868

2028

1294

2029

1927

2030

2634

2031

3238

2032

3737

Molecule profile

Details & specifications

Molecule

Eplontersen

Innovator

ASTRAZENECA AB

Dosage Form

Subcutaneous Injection

Strength

45 mg base/0.8 mL

Therapeutic Category

Neuroprotective

Usage

To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.